Toxicity Considerations in HR+ Breast Cancer Treatment

Opinion
Video

Virginia Kaklamani, MD, offers clinical insights on treatment toxicity considerations in HR+ breast cancer, and the Oncology Brothers outline key takeaways from the discussion.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content
Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

Chemotherapy Confers No Survival Benefit in Older Breast Cancer Population

Roman Fabbricatore
September 5th 2025
Article
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
September 5th 2025
Podcast
Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Ariana Pelosci
September 5th 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
September 5th 2025
Podcast
FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

MammaPrint Displays Predictive Utility for Chemo in HR+/HER2– Breast Cancer

Roman Fabbricatore
September 5th 2025
Article
Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis.

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

Sherry Shen, MD;Bethina Liu, MD;Chad Fanti, MD;Maria Bromberg, MPH;Yuan Chen, PhD;Cassandra Chang;Neil M. Iyengar, MD
September 5th 2025
Article